A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Amer M ZeidanMaya RidingerTara L Lin Pamela S BeckerGary J SchillerPrapti A PatelAlexander I SpiraMichaela L TsaiErrin SamuëlszSandra L SilbermanMark ErlanderEunice S Wang

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

The onvansertib and decitabine combination was well tolerated and had antileukemic activity particularly in patients with target engagement and decreased mutant ctDNA following treatment. This combination will be further investigated in the ongoing phase II trial.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
acute lymphoblastic leukemia
social media
randomized controlled trial
clinical trial
open label
atomic force microscopy
study protocol
circulating tumor
double blind